{"hands_on_practices": [{"introduction": "Allelic heterogeneity, the existence of multiple different pathogenic alleles at a single locus, is a common feature of many recessive genetic disorders. This exercise uses the principles of Hardy-Weinberg equilibrium to explore a key consequence of this phenomenon: the relative proportion of affected individuals who are compound heterozygotes versus homozygotes. Understanding this relationship is fundamental for population genetics and has practical implications for designing genetic screening strategies. [@problem_id:5037530]", "problem": "A fully recessive Mendelian disease exhibits allelic heterogeneity at a single locus: there are $k$ distinct pathogenic alleles at this locus, each segregating at equal frequency in the population. Let the total population frequency of all pathogenic alleles at this locus be $r$, so that the frequency of each specific pathogenic allele is $r/k$. Assume a large, randomly mating population at Hardy–Weinberg equilibrium with no selection, migration, or mutation over the timescale considered. Affected individuals are those who inherit any pair of pathogenic alleles at this locus (either the same allele twice, i.e., a homozygote, or two different pathogenic alleles, i.e., a compound heterozygote). Using the Hardy–Weinberg assumptions and the rules for multi-allelic genotype frequencies, derive from first principles the expected fraction of affected individuals who are compound heterozygotes versus homozygotes, expressed purely as functions of $k$ (independent of $r$). Provide your final result as a row matrix $\\big[$fraction compound heterozygotes$\\,\\,\\,\\,\\text{fraction homozygotes}\\big]$. No rounding is required.", "solution": "The problem is validated as scientifically grounded, well-posed, objective, and internally consistent. It is a standard problem in population genetics that can be solved from first principles.\n\nLet the set of $k$ distinct pathogenic alleles at the specified locus be denoted by $\\{A_1, A_2, \\ldots, A_k\\}$. The total frequency of all pathogenic alleles in the population is given as $r$. Since each of these $k$ alleles is stated to segregate at an equal frequency, the frequency of any specific pathogenic allele $A_i$ (for $i \\in \\{1, 2, \\ldots, k\\}$) is:\n$$ p(A_i) = \\frac{r}{k} $$\nThe population is assumed to be in Hardy–Weinberg equilibrium. For a locus with multiple alleles, the genotype frequencies are determined by the terms in the expansion of the square of the sum of all allele frequencies.\n\nAn individual is affected by this fully recessive disease if and only if their genotype consists of two pathogenic alleles. This can happen in two mutually exclusive ways:\n1. The individual is a homozygote for a pathogenic allele, having a genotype of the form $A_iA_i$.\n2. The individual is a compound heterozygote, having a genotype of the form $A_iA_j$ where $i \\neq j$.\n\nWe will now calculate the total population frequency for each of these categories.\n\nFirst, consider the affected homozygotes. The frequency of a specific homozygous genotype $A_iA_i$ is given by the square of the allele's frequency:\n$$ p(A_iA_i) = (p(A_i))^2 = \\left(\\frac{r}{k}\\right)^2 = \\frac{r^2}{k^2} $$\nSince there are $k$ distinct pathogenic alleles, there are $k$ possible homozygous genotypes that result in the disease phenotype. The total frequency of individuals who are affected homozygotes, which we denote as $F_{hom}$, is the sum of the frequencies of these $k$ genotypes:\n$$ F_{hom} = \\sum_{i=1}^{k} p(A_iA_i) = \\sum_{i=1}^{k} \\frac{r^2}{k^2} = k \\times \\frac{r^2}{k^2} = \\frac{r^2}{k} $$\n\nNext, consider the affected compound heterozygotes. The frequency of a specific compound heterozygous genotype $A_iA_j$ (where $i \\neq j$) is given by:\n$$ p(A_iA_j) = 2 p(A_i) p(A_j) = 2 \\left(\\frac{r}{k}\\right) \\left(\\frac{r}{k}\\right) = \\frac{2r^2}{k^2} $$\nTo find the total frequency of all compound heterozygotes, we must sum this frequency over all possible distinct pairs of pathogenic alleles. The number of ways to choose two distinct alleles from the set of $k$ pathogenic alleles is given by the binomial coefficient $\\binom{k}{2}$:\n$$ \\binom{k}{2} = \\frac{k(k-1)}{2} $$\nThe total frequency of individuals who are affected compound heterozygotes, denoted as $F_{comp.het}$, is the number of such genotypes multiplied by the frequency of each:\n$$ F_{comp.het} = \\binom{k}{2} \\times \\frac{2r^2}{k^2} = \\frac{k(k-1)}{2} \\times \\frac{2r^2}{k^2} = \\frac{k(k-1)r^2}{k^2} = \\frac{(k-1)r^2}{k} $$\n\nThe total frequency of all affected individuals in the population, $F_{affected}$, is the sum of the frequencies of the affected homozygotes and the affected compound heterozygotes:\n$$ F_{affected} = F_{hom} + F_{comp.het} = \\frac{r^2}{k} + \\frac{(k-1)r^2}{k} = \\frac{r^2 + (k-1)r^2}{k} = \\frac{r^2(1 + k - 1)}{k} = \\frac{kr^2}{k} = r^2 $$\nThis result is intuitively correct, as the probability of inheriting a pathogenic allele is $r$, so under random mating, the probability of inheriting two such alleles is $r \\times r = r^2$.\n\nThe problem requires the fraction of *affected* individuals who are compound heterozygotes versus homozygotes.\n\nThe fraction of affected individuals who are compound heterozygotes is the ratio of the frequency of compound heterozygotes to the total frequency of affected individuals:\n$$ f_{comp.het} = \\frac{F_{comp.het}}{F_{affected}} = \\frac{\\frac{(k-1)r^2}{k}}{r^2} = \\frac{k-1}{k} $$\n\nThe fraction of affected individuals who are homozygotes is the ratio of the frequency of homozygotes to the total frequency of affected individuals:\n$$ f_{hom} = \\frac{F_{hom}}{F_{affected}} = \\frac{\\frac{r^2}{k}}{r^2} = \\frac{1}{k} $$\n\nAs required, these fractions are expressed purely as functions of $k$. As a check, their sum is $f_{comp.het} + f_{hom} = \\frac{k-1}{k} + \\frac{1}{k} = \\frac{k}{k} = 1$.\n\nThe final answer is requested as a row matrix: $[\\text{fraction compound heterozygotes} \\quad \\text{fraction homozygotes}]$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n\\frac{k-1}{k} & \\frac{1}{k}\n\\end{pmatrix}\n}\n$$", "id": "5037530"}, {"introduction": "Beyond just counting alleles, understanding their functional differences is crucial, as this directly relates to genotype-phenotype correlations. This problem delves into the molecular mechanisms of allelic heterogeneity by contrasting a simple loss-of-function allele with a dominant-negative allele in a gene encoding a multimeric protein. By quantitatively modeling the impact on protein function, you will gain a deeper appreciation for why different mutations in the same gene can lead to vastly different clinical severities. [@problem_id:5037562]", "problem": "A single gene, denoted $G$, encodes a homotrimeric protein complex in which $3$ identical subunits assemble to form the active enzyme. Consider two distinct pathogenic variants (allelic heterogeneity) within $G$ that are both observed in unrelated families with the same clinical diagnosis, denoted $\\mathcal{P}$, but with different severity distributions across affected individuals.\n\nVariant $1$ is a nonsense mutation that triggers Nonsense-Mediated Decay (NMD), such that the mutant allele produces approximately $0$ protein. Variant $2$ is a missense mutation whose product is stable, incorporates into the trimer, and renders any trimer that contains at least one mutant subunit catalytically inactive, while trimers composed entirely of wild-type subunits retain full activity.\n\nAssume heterozygous individuals produce equal amounts of transcript from each allele unless degraded by NMD, assembly of subunits into trimers is random, and total cellular protein levels from $G$ are otherwise constrained by normal homeostatic regulation. Empirically, clinicians classify phenotype $\\mathcal{P}$ when total cellular enzymatic activity from $G$ falls below $60\\%$ of the population mean, and they classify severe $\\mathcal{P}$ when activity falls below $20\\%$ of the mean.\n\nWhich option best defines a dominant-negative effect and correctly describes a plausible mechanistic explanation for why both Variant $1$ (loss-of-function via NMD) and Variant $2$ (missense) cause the same clinical diagnosis $\\mathcal{P}$ yet with different severity distributions among heterozygous carriers?\n\nA. A dominant-negative effect occurs when a mutant gene product antagonizes the function of the wild-type product in the same cell. In a heterozygote for Variant $2$, both wild-type and mutant subunits are produced at roughly $50\\%$ each and assemble at random into trimers; only trimers with $3$ wild-type subunits are functional, so the fraction of functional complexes is much less than in a Variant $1$ heterozygote, where NMD eliminates mutant subunits and yields a reduced but unpoisoned pool of wild-type trimers. Thus, both variants can cross the $60\\%$ activity threshold for $\\mathcal{P}$, but Variant $2$ is more likely to produce severe $\\mathcal{P}$ (activity near or below $20\\%$), while Variant $1$ tends to produce milder $\\mathcal{P}$.\n\nB. A dominant-negative effect is a gain-of-function mechanism where the mutant allele produces more active protein than normal. Variant $2$ would therefore be milder than Variant $1$, because Variant $1$ heterozygotes have no protein and thus less activity than Variant $2$ heterozygotes, who have extra activity from the mutant subunits.\n\nC. A dominant-negative effect occurs when different genes in the same pathway yield the same phenotype. Variant $1$ and Variant $2$ exemplify locus heterogeneity; their similar severity distributions arise because both reduce total protein amount equally in heterozygotes.\n\nD. A dominant-negative effect occurs when a mutant protein fails to be expressed at all. In a heterozygote for Variant $2$, the functional fraction of dimers would be $50\\%$, which exceeds the $60\\%$ threshold for $\\mathcal{P}$, so Variant $2$ is asymptomatic, whereas Variant $1$ causes severe disease because total protein is reduced to $25\\%$ of normal.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\n- A single gene, $G$, encodes a homotrimeric protein complex composed of $3$ identical subunits.\n- Two distinct pathogenic variants (allelic heterogeneity) in $G$ cause the same clinical diagnosis, $\\mathcal{P}$.\n- Variant $1$: A nonsense mutation that triggers Nonsense-Mediated Decay (NMD). The mutant allele produces approximately $0$ protein.\n- Variant $2$: A missense mutation. Its protein product is stable, incorporates into the trimer, and renders any trimer with at least one mutant subunit catalytically inactive. Trimers of entirely wild-type subunits have full activity.\n- Heterozygous individuals produce equal amounts of transcript from each allele unless NMD occurs.\n- Assembly of subunits into trimers is random.\n- Total cellular protein levels from $G$ are constrained by normal homeostatic regulation.\n- Phenotype $\\mathcal{P}$ is classified when total cellular enzymatic activity is below $60\\%$ of the mean.\n- Severe $\\mathcal{P}$ is classified when total cellular enzymatic activity is below $20\\%$ of the mean.\n- The question asks for the best definition of a dominant-negative effect and a mechanistic explanation for the phenotypes and severity differences in heterozygotes for Variant $1$ and Variant $2$.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is based on fundamental principles of molecular and medical genetics. The concepts of allelic heterogeneity, homotrimeric proteins, nonsense-mediated decay (NMD), missense mutations, dominant-negative effects, and haploinsufficiency are all well-established and central to the field. The scenario described is a classic textbook model for illustrating the difference between haploinsufficiency and a dominant-negative mechanism.\n2.  **Well-Posed:** The problem provides all necessary information to perform a quantitative analysis of protein activity for both variant types. The assumptions (random assembly, equal transcript production) are explicitly stated, allowing for the calculation of expected enzyme activity levels. A unique, stable, and meaningful solution can be derived from the given data and principles.\n3.  **Objective:** The problem statement is written in precise, objective, and unbiased scientific language. Key terms are used correctly, and the conditions for the phenotype are defined with specific quantitative thresholds ($60\\%$ and $20\\%$).\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically sound, well-posed, and objective. I will proceed with a full solution.\n\n## SOLUTION DERIVATION\n\nLet $W$ denote the wild-type allele and $M$ denote a mutant allele. Let $P_W$ be the wild-type protein subunit and $P_M$ be the mutant protein subunit. The active enzyme is a homotrimer. A normal, wild-type individual has the genotype $W/W$, produces $100\\%$ $P_W$ subunits, and all resulting trimers ($P_W P_W P_W$) are active. Their total cellular enzymatic activity is defined as the baseline $100\\%$.\n\n### Analysis of Variant 1 Heterozygote ($W/M_1$)\nA heterozygote for Variant $1$ ($W/M_1$) has one wild-type allele and one allele with a nonsense mutation. The problem states that this mutation triggers NMD, and the mutant allele produces approximately $0$ protein. The wild-type allele continues to produce $P_W$ subunits. Assuming no dosage compensation, a single functional allele produces $50\\%$ of the normal amount of protein. Therefore, the total amount of protein from gene $G$ in a $W/M_1$ heterozygote is $50\\%$ of that in a $W/W$ individual, and all of these subunits are $P_W$.\n- Subunit pool: Approximately $100\\%$ $P_W$, but at an overall concentration that is $50\\%$ of normal.\n- Trimer formation: All trimers formed will be $P_W P_W P_W$.\n- Total activity: Since all trimers are functional but the total number of trimers is only $50\\%$ of the normal amount, the total cellular enzymatic activity is $50\\%$ of the mean. This mechanism, where a $50\\%$ reduction in protein product due to a loss-of-function allele causes disease, is known as haploinsufficiency.\n- Phenotype: Activity is $50\\%$. Since $50\\% < 60\\%$, the individual has phenotype $\\mathcal{P}$. Since $50\\% > 20\\%$, the phenotype is not severe.\n\n### Analysis of Variant 2 Heterozygote ($W/M_2$)\nA heterozygote for Variant $2$ ($W/M_2$) has one wild-type allele and one allele with a missense mutation. The problem states the mutant protein ($P_{M2}$) is stable and is produced at equal levels to the wild-type protein. Thus, the total amount of protein subunits (wild-type + mutant) is normal ($100\\%$).\n- Subunit pool: $50\\%$ $P_W$ and $50\\%$ $P_{M2}$.\n- Trimer formation: Subunits assemble randomly. The probability of picking a $P_W$ subunit is $p = 0.5$, and the probability of picking a $P_{M2}$ subunit is $q = 0.5$. The trimer is formed by $3$ random choices from this pool. The distribution of trimer types follows the binomial expansion of $(p + q)^3$:\n  $$ (p + q)^3 = p^3 + 3p^2q + 3pq^2 + q^3 $$\n- Active trimers: According to the problem, only trimers composed entirely of wild-type subunits ($P_W P_W P_W$) are active. Any trimer containing at least one $P_{M2}$ subunit is inactive. This is the definition of a dominant-negative effect, where the mutant product interferes with or \"poisons\" the function of the wild-type product.\n- Fraction of active trimers: The probability of forming a fully wild-type, active trimer ($P_W P_W P_W$) is $p^3$.\n  $$ \\text{Fraction of active trimers} = (0.5)^3 = 0.125 $$\n- Total activity: Since the total number of trimers is normal, the total cellular enzymatic activity is equal to the fraction of active trimers, which is $12.5\\%$ of the mean.\n- Phenotype: Activity is $12.5\\%$. Since $12.5\\% < 60\\%$, the individual has phenotype $\\mathcal{P}$. Since $12.5\\% < 20\\%$, the phenotype is severe.\n\n### Summary\n- Variant $1$ (haploinsufficiency) leads to $50\\%$ activity and a milder form of $\\mathcal{P}$.\n- Variant $2$ (dominant-negative) leads to $12.5\\%$ activity and a severe form of $\\mathcal{P}$.\nThis quantitative analysis explains why both variants cause the same disease ($\\mathcal{P}$) but with different severity distributions.\n\n## OPTION-BY-OPTION ANALYSIS\n\n**A. A dominant-negative effect occurs when a mutant gene product antagonizes the function of the wild-type product in the same cell. In a heterozygote for Variant $2$, both wild-type and mutant subunits are produced at roughly $50\\%$ each and assemble at random into trimers; only trimers with $3$ wild-type subunits are functional, so the fraction of functional complexes is much less than in a Variant $1$ heterozygote, where NMD eliminates mutant subunits and yields a reduced but unpoisoned pool of wild-type trimers. Thus, both variants can cross the $60\\%$ activity threshold for $\\mathcal{P}$, but Variant $2$ is more likely to produce severe $\\mathcal{P}$ (activity near or below $20\\%$), while Variant $1$ tends to produce milder $\\mathcal{P}$.**\n- The definition of a dominant-negative effect is correct.\n- The description of the mechanism for Variant $2$ is correct.\n- The comparison with the Variant $1$ mechanism (haploinsufficiency) is correct.\n- The analysis of the resulting activity levels and phenotypes is consistent with our derivation: Variant $1$ activity is $50\\%$ (milder $\\mathcal{P}$), and Variant $2$ activity is $12.5\\%$ (severe $\\mathcal{P}$). Both are below the $60\\%$ threshold for $\\mathcal{P}$.\n**Verdict: Correct.**\n\n**B. A dominant-negative effect is a gain-of-function mechanism where the mutant allele produces more active protein than normal. Variant $2$ would therefore be milder than Variant $1$, because Variant $1$ heterozygotes have no protein and thus less activity than Variant $2$ heterozygotes, who have extra activity from the mutant subunits.**\n- The definition of a dominant-negative effect is incorrect. It is a dominant form of loss-of-function, not a gain-of-function.\n- The conclusion that Variant $2$ is milder is incorrect, as our derivation shows it is more severe ($12.5\\%$ activity vs. $50\\%$).\n- The premise that Variant $1$ heterozygotes have \"no protein\" is incorrect; they have $50\\%$ of the normal amount of wild-type protein.\n**Verdict: Incorrect.**\n\n**C. A dominant-negative effect occurs when different genes in the same pathway yield the same phenotype. Variant $1$ and Variant $2$ exemplify locus heterogeneity; their similar severity distributions arise because both reduce total protein amount equally in heterozygotes.**\n- The definition provided is for locus heterogeneity, not a dominant-negative effect.\n- The statement that Variant $1$ and $2$ exemplify locus heterogeneity is incorrect. They are different mutations in the same gene ($G$), which is an example of allelic heterogeneity.\n- The problem states the severity distributions are *different*, not similar.\n- The variants do not reduce activity equally ($50\\%$ vs. $12.5\\%$).\n**Verdict: Incorrect.**\n\n**D. A dominant-negative effect occurs when a mutant protein fails to be expressed at all. In a heterozygote for Variant $2$, the functional fraction of dimers would be $50\\%$, which exceeds the $60\\%$ threshold for $\\mathcal{P}$, so Variant $2$ is asymptomatic, whereas Variant $1$ causes severe disease because total protein is reduced to $25\\%$ of normal.**\n- The definition of a dominant-negative effect is incorrect. Failure to be expressed describes a null allele, which can cause haploinsufficiency, not a dominant-negative effect (which requires an interfering protein product).\n- The problem states the protein is a homotrimer, not a homodimer. This is a critical error.\n- Even for a dimer, the fraction of functional complexes ($P_W P_W$) would be $(0.5)^2 = 0.25$, or $25\\%$, not $50\\%$.\n- The conclusions about phenotypes are reversed and based on incorrect calculations. Variant $2$ is not asymptomatic, and Variant $1$ does not cause severe disease and its protein level is not reduced to $25\\%$.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5037562"}, {"introduction": "We now shift our focus to locus heterogeneity, where mutations in multiple distinct genes can result in an identical phenotype. This exercise provides a probabilistic framework to quantify how the number of contributing genes, and their relative prevalence, affects the likelihood that two unrelated patients share the same underlying genetic cause. This concept is central to modern gene discovery efforts and the interpretation of genetic data in clinical practice. [@problem_id:5037539]", "problem": "An autosomal phenotype exhibits locus heterogeneity: variants in any of $m$ distinct genes (loci) can independently cause the same clinical presentation. Among affected individuals, let $f_{i}$ denote the fraction attributable to locus $i$, with $\\sum_{i=1}^{m} f_{i} = 1$ and $0 \\leq f_{i} \\leq 1$. Consider $2$ unrelated affected patients sampled uniformly at random from the population of affected individuals. Using only core definitions of probability and the independence implied by unrelated sampling, derive from first principles an analytic expression for the probability that these $2$ patients share the same causal gene (i.e., both patients’ etiologies trace to the same locus). Then, interpret this expression in the limiting case where one locus dominates (for example, $f_{1} \\to 1$) and in the case where all loci contribute equally (i.e., $f_{i} = 1/m$ for all $i$). Express your final probability as a closed-form expression in terms of $m$ and the vector $(f_{1}, f_{2}, \\dots, f_{m})$. No numerical rounding is required.", "solution": "The problem is first assessed for validity. The givens are: an autosomal phenotype with locus heterogeneity involving $m$ distinct genes; the fraction of affected individuals attributable to locus $i$ is $f_{i}$, with $\\sum_{i=1}^{m} f_{i} = 1$ and $0 \\le f_{i} \\le 1$; and we are considering $2$ unrelated, randomly sampled affected patients. The problem is scientifically grounded in the well-established genetic principle of locus heterogeneity, is mathematically well-posed with sufficient and consistent information, and is stated objectively. It is therefore deemed a valid problem.\n\nLet $C_1$ and $C_2$ be discrete random variables representing the causal locus for the first and second patient, respectively. The set of possible values for both $C_1$ and $C_2$ is the set of loci $\\{1, 2, \\dots, m\\}$.\n\nAccording to the problem statement, the fraction of affected individuals for whom locus $i$ is causal is $f_i$. This fraction can be interpreted as the probability that a single, randomly selected affected patient has their condition caused by locus $i$. Thus, for any locus $i \\in \\{1, 2, \\dots, m\\}$, the probability mass function for $C_1$ and $C_2$ is:\n$$P(C_1 = i) = f_i$$\n$$P(C_2 = i) = f_i$$\n\nWe are asked to find the probability that the two patients share the same causal gene. This is the event $C_1 = C_2$. This event can be partitioned into $m$ mutually exclusive sub-events: the event that both patients' conditions are caused by locus $1$, or both by locus $2$, and so on, up to locus $m$. Let $A_i$ be the event that both patients share locus $i$ as the cause, i.e., $A_i = \\{C_1 = i \\text{ and } C_2 = i\\}$.\n\nThe total probability of the event $C_1 = C_2$ is the sum of the probabilities of these mutually exclusive events, by the sum rule of probability:\n$$P(C_1 = C_2) = P(A_1 \\cup A_2 \\cup \\dots \\cup A_m) = \\sum_{i=1}^{m} P(A_i)$$\n$$P(C_1 = C_2) = \\sum_{i=1}^{m} P(C_1 = i \\text{ and } C_2 = i)$$\n\nThe problem states that the two patients are \"unrelated\" and \"sampled uniformly at random\". The term \"unrelated\" in genetics and probability implies statistical independence. Therefore, the event that patient $1$ has a condition caused by locus $i$ is independent of the event that patient $2$ has a condition caused by locus $i$. Due to this independence, the joint probability can be calculated as the product of the marginal probabilities:\n$$P(C_1 = i \\text{ and } C_2 = i) = P(C_1 = i) \\times P(C_2 = i)$$\n\nSubstituting the known probabilities, we get:\n$$P(C_1 = i \\text{ and } C_2 = i) = f_i \\times f_i = f_i^2$$\n\nNow, we substitute this result back into the summation to obtain the final analytical expression for the probability that the two patients share the same causal locus:\n$$P(C_1 = C_2) = \\sum_{i=1}^{m} f_i^2$$\nThis expression is the sum of the squared fractions for all contributing loci.\n\nWe now interpret this result in the two specified limiting cases.\n\nCase 1: One locus dominates.\nLet us assume, without loss of generality, that locus $1$ is the dominant locus, so its contribution $f_1$ approaches $1$. The constraint $\\sum_{i=1}^{m} f_i = 1$ requires that if $f_1 \\to 1$, then $f_i \\to 0$ for all $i \\ne 1$. We evaluate the limit of our probability expression:\n$$\\lim_{f_1 \\to 1} \\left( \\sum_{i=1}^{m} f_i^2 \\right) = \\lim_{f_1 \\to 1} \\left( f_1^2 + \\sum_{i=2}^{m} f_i^2 \\right)$$\nSince this is a finite sum and the limits exist, we can write:\n$$(\\lim_{f_1 \\to 1} f_1^2) + \\sum_{i=2}^{m} (\\lim_{f_i \\to 0} f_i^2) = 1^2 + \\sum_{i=2}^{m} 0^2 = 1 + 0 = 1$$\nThe interpretation is that if a single gene is responsible for nearly all cases of a phenotype ($f_1 \\approx 1$), it becomes almost certain ($P \\to 1$) that any two randomly chosen affected individuals will both have the condition due to that same predominant gene.\n\nCase 2: All loci contribute equally.\nIn this case, the fraction for each locus is the same: $f_i = \\frac{1}{m}$ for all $i \\in \\{1, 2, \\dots, m\\}$. We substitute this into our derived expression:\n$$P(C_1 = C_2) = \\sum_{i=1}^{m} \\left( \\frac{1}{m} \\right)^2 = \\sum_{i=1}^{m} \\frac{1}{m^2}$$\nThe summation consists of adding the term $\\frac{1}{m^2}$ to itself $m$ times.\n$$P(C_1 = C_2) = m \\times \\frac{1}{m^2} = \\frac{m}{m^2} = \\frac{1}{m}$$\nThe interpretation is that if there are $m$ equally frequent genetic causes for a condition, the probability that two unrelated patients share the same cause is $\\frac{1}{m}$. As the number of genetic causes $m$ increases (i.e., as heterogeneity becomes greater), the probability of a match decreases.", "answer": "$$\\boxed{\\sum_{i=1}^{m} f_{i}^{2}}$$", "id": "5037539"}]}